NOV 24, 2021 4:33 AM PST

Can Cannabis Treat Chemotherapy-induced Peripheral Neuropathy?

Platinum-based chemotherapies such as oxaliplatin are used to treat gastrointestinal tumors, especially in the advanced setting. Although demonstrated to be an effective treatment, it is one of the most neurotoxic types of chemotherapy. It has been shown that more than 90% of oxaliplatin recipients experience acute neuropathy. This neuropathy, known as chemotherapy-induced peripheral neuropathy (CIPN), can be highly debilitating. Currently, interventions to treat or prevent this condition are limited. The role of cannabis in treating cancer-related pain and certain neuropathic conditions has been studied. However, clinical evidence on the effectiveness of cannabis for treating CIPN is lacking. In February 2021, the results of a retrospective analysis evaluating cannabis for this treatment purpose were published.

In this review, the medical records of 768 patients who had received chemotherapy regimens, including oxaliplatin, were reviewed. Patients were separated into those with no cannabis use, those who used cannabis before oxaliplatin, and those who used cannabis after oxaliplatin. Results demonstrated a protective effect of cannabis that was statistically significant and more robust in those patients who used cannabis before treatment with oxaliplatin. Although this study was retrospective in nature, strengths of this study include data reliability and length of the study period.

The mechanism through which cannabis impacts CIPN is not well understood; however, the results of an animal study published in November 2021 suggest that oxaliplatin-induced neuropathy is modified by cannabis through specific cannabinoid receptors such as CB1. As such, potential therapeutic targets involving the endocannabinoid system are being described. Prospective trials further investigating the use of cannabis in the prevention and treatment of CIPN in humans are on the horizon.

 

Sources: Journal of Clinical Medicine, Therapeutic Advances in Medical Oncology, Neurotoxicity Research

About the Author
  • Dr. Christopher DiMaio is a Science Writer at Labroots. He received his MD from Penn State College of Medicine in 2014. His academic and professional interests include Neuroscience, Behavioral health, Immunology, and Healthcare improvement, among others. He is an active part of his community.
You May Also Like
JUL 15, 2021
Cannabis Sciences
Cannabis Terpenes Provide Pain Relief in Mice
JUL 15, 2021
Cannabis Terpenes Provide Pain Relief in Mice
Cannabis terpenes, the part of cannabis plants responsible for its smell and taste, may be able to relieve pain both by ...
AUG 05, 2021
Health & Medicine
Health Professionals Working with Cystic Fibrosis Patients Lack Cannabis Confidence
AUG 05, 2021
Health Professionals Working with Cystic Fibrosis Patients Lack Cannabis Confidence
The quality of dialogue and understanding that clinical healthcare and social care workers have around cannabis and cyst ...
SEP 09, 2021
Clinical & Molecular DX
A Drug Test for Synthetic Cannabis Use
SEP 09, 2021
A Drug Test for Synthetic Cannabis Use
Designer drugs are synthetic analogs of prohibited substances such as cocaine and LSD made in clandestine laboratories a ...
NOV 30, 2021
Cannabis Sciences
Terpene-Mediated Modulation of Cannabinoid Activity
NOV 30, 2021
Terpene-Mediated Modulation of Cannabinoid Activity
A popular theory – the “entourage effect” – has been gaining traction amongst the cannabis scien ...
JAN 08, 2022
Cannabis Sciences
Hemp Supercapacitors Outperform Other Kinds of Batteries
JAN 08, 2022
Hemp Supercapacitors Outperform Other Kinds of Batteries
Research on hemp’s many uses is in its infancy, but recent studies suggest that hemp batteries can outperform lith ...
JAN 20, 2022
Cannabis Sciences
Cannabinoids Bind Spike Proteins of SARS-CoV-2 & Emerging Variants to Prevent Infection in vitro
JAN 20, 2022
Cannabinoids Bind Spike Proteins of SARS-CoV-2 & Emerging Variants to Prevent Infection in vitro
As the pandemic has progressed, multiple variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have e ...
Loading Comments...